Wiebe J, Rai H, Kuna C, et al. - Angiographic anti-restenotic efficacy of stenting with everolimus-eluting stents (EES) for the treatment of in-stent restenosis (ISR) in daily practice was found to be comparable to that reported in randomized clinical trials and less favorable compared with its performance in patients receiving stenting for de novo disease.

• A study including 426 patients with ISR (mean age was 66.8 ± 9.9 years) who were treated with EES and had undergone angiographic follow-up.

• Overall 459 lesions were treated, and a reduction in the diameter stenosis was evident, from 64.3 ± 19.1% (preprocedural) to 12.0 ± 6.4% (postprocedural).

• The in-segment diameter stenosis and in-stent late luminal loss, at 6–8 months angiographic follow-up, was reported to be 38.3 ± 21.7% and 0.54 ± 0.74 mm, respectively, in the treated area analysis.

• For recurrent binary restenosis, a rate of 25.7% was estimated.